Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ2O8V)

• Drug Name: CHF-3381 Drug Info
• Synonyms: Indantadol; UNII-Z3867B9SQP; Z3867B9SQP; Indantadol [INN]; CHF 3381; N-(2-Indanyl)glycinamide hydrochloride; 2-(2-indanylamino)acetamide; SCHEMBL399565; ZINC9005; MolPort-015-094-768; MNLULKBKWKTZPE-UHFFFAOYSA-N; AKOS009549166

Indication

Disease Entry	ICD 11	Status	REF
Neuropathic pain	8E43.0	Phase 2	[1]

• Therapeutic Class: Analgesics
• Cross-matching ID:
  PubChem CID: 10198454
  CAS Number: CAS 202914-18-9
  TTD Drug ID: DMQ2O8V

Molecule-Related Drug Atlas

Drug(s) Targeting N-methyl-D-aspartate receptor (NMDAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[3]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[4]
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[5]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[6]
Felbamate	DM1V5ZS	Epilepsy	8A60-8A68	Approved	[7]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[8]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[9]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[10]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[11]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[12]

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[13]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[14]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[15]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[16]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[17]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[18]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[19]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[20]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[21]
Budipine	DMODHQI	Migraine	8A80	Approved	[22]

Drug(s) Targeting Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[23]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[24]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[25]
Isocarboxazid	DMAF1NB	Depression	6A70-6A7Z	Approved	[26]
TRYPTAMINE	DMAFPHB	N. A.	N. A.	Phase 3	[27]
Psoralen	DMIZJ8M	N. A.	N. A.	Phase 3	[28]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[29]
CX157	DMS2WB5	Mood disorder	6A60-6E23	Phase 2	[30]
PIPERINE	DMYEAB1	Vitiligo	ED63.0	Phase 1/2	[31]
Desoxypeganine	DMTR7EH	Alcohol dependence	6C40.2	Phase 1	[32]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[2]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[2]
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Antagonist	[2]

References

• [1] Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10(9):636-44.
• [2] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [3] Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
• [4] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [5] Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
• [6] Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
• [7] Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
• [8] The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
• [9] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [10] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
• [11] Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
• [12] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
• [13] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [14] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [15] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [17] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [18] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [19] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [20] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [22] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
• [23] Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
• [24] Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
• [25] Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
• [26] MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
• [27] Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
• [28] Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
• [29] Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
• [30] Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
• [31] Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
• [32] Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.